BRPI0818340A2 - Produto de dispersão sólida de fármacos baseados em n-aril uréia - Google Patents

Produto de dispersão sólida de fármacos baseados em n-aril uréia

Info

Publication number
BRPI0818340A2
BRPI0818340A2 BRPI0818340A BRPI0818340A2 BR PI0818340 A2 BRPI0818340 A2 BR PI0818340A2 BR PI0818340 A BRPI0818340 A BR PI0818340A BR PI0818340 A2 BRPI0818340 A2 BR PI0818340A2
Authority
BR
Brazil
Prior art keywords
based solid
solid drug
dispersion product
drug dispersion
aryl urea
Prior art date
Application number
Other languages
English (en)
Inventor
Rudolf Schroeder
Tanja Heitermann
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of BRPI0818340A2 publication Critical patent/BRPI0818340A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0818340 2007-10-19 2008-10-17 Produto de dispersão sólida de fármacos baseados em n-aril uréia BRPI0818340A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99961807P 2007-10-19 2007-10-19
PCT/EP2008/064076 WO2009050291A2 (en) 2007-10-19 2008-10-17 Solid dispersion product of n-aryl urea-based drugs

Publications (1)

Publication Number Publication Date
BRPI0818340A2 true BRPI0818340A2 (pt) 2015-04-22

Family

ID=40089463

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818340 BRPI0818340A2 (pt) 2007-10-19 2008-10-17 Produto de dispersão sólida de fármacos baseados em n-aril uréia

Country Status (18)

Country Link
EP (1) EP2197425A2 (pt)
JP (1) JP2011500649A (pt)
KR (1) KR20100087170A (pt)
CN (1) CN101827584A (pt)
AU (1) AU2008313622A1 (pt)
BR (1) BRPI0818340A2 (pt)
CA (1) CA2699301A1 (pt)
CO (1) CO6270206A2 (pt)
CR (1) CR11442A (pt)
DO (1) DOP2010000117A (pt)
EC (1) ECSP10010183A (pt)
GT (1) GT201000102A (pt)
MX (1) MX2010004291A (pt)
PA (1) PA8800101A1 (pt)
RU (1) RU2010119929A (pt)
UA (1) UA100865C2 (pt)
WO (1) WO2009050291A2 (pt)
ZA (1) ZA201002095B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
RU2566716C2 (ru) 2010-06-09 2015-10-27 Эббви Бахамаз Лтд. Твердые дисперсии, содержащие ингибиторы киназ
JP6150813B2 (ja) 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
CA2856406C (en) * 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
WO2008055966A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
ECSP10010183A (es) 2010-06-29
RU2010119929A (ru) 2011-11-27
UA100865C2 (ru) 2013-02-11
AU2008313622A1 (en) 2009-04-23
MX2010004291A (es) 2010-08-02
WO2009050291A2 (en) 2009-04-23
CR11442A (es) 2010-09-06
DOP2010000117A (es) 2010-05-15
CN101827584A (zh) 2010-09-08
ZA201002095B (en) 2011-11-30
JP2011500649A (ja) 2011-01-06
CA2699301A1 (en) 2009-04-23
WO2009050291A3 (en) 2010-04-08
CO6270206A2 (es) 2011-04-20
EP2197425A2 (en) 2010-06-23
GT201000102A (es) 2012-03-12
KR20100087170A (ko) 2010-08-03
PA8800101A1 (es) 2009-05-15

Similar Documents

Publication Publication Date Title
LTC2140867I2 (lt) Farmacinė kompozicija
BRPI0818339A2 (pt) Produto de dispersão sólida contendo composto à base de n-aril uréia
BRPI0816730A2 (pt) sistema de distribuição de produto
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
BRPI0821876A8 (pt) sistemas e métodos para administração de medicação
DK2692341T3 (da) Misbrugs-resistent lægemiddelformulering
BRPI0812861A2 (pt) Conexão luer de segurança
BRPI0814639A2 (pt) Monitor de carregamento
DK2151438T3 (da) Lægemiddel indeholdende PPAR-Deltaagonist
BRPI0820381A2 (pt) Formulações farmacêuticas
HRP20181843T1 (hr) Sredstvo za izdavanje lijeka za životinje
BRPI0920521A2 (pt) combinação farmacêutica
BRPI0721651A2 (pt) Composição farmacêutica
BRPI0912972A2 (pt) Produtos lácteos granulados
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0817310A2 (pt) Ensaio de monitoramento de fármaco
BRPI0813753A2 (pt) Produto pré-impregnado
IL242028A0 (en) A system for dispensing doses of medicine operated by means of a micro-pump
ATE531278T1 (de) Süsswaren-produkt
EP2154966A4 (en) BENZIMIDAZOLE AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BRPI0919331A2 (pt) derivados de pirazolo piridina, composições farmacêuticas e métodos associados
BRPI0921654A2 (pt) formulação farmacêutica
BRPI0716883A2 (pt) Acumulador de produto giratório

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.